Selective inhibition of the p38α MAPK–MK2 axis inhibits inflammatory cues including inflammasome priming signals

p38α activation of multiple effectors may underlie the failure of global p38α inhibitors in clinical trials. A unique inhibitor (CDD-450) was developed that selectively blocked p38α activation of the proinflammatory kinase MK2 while sparing p38α activation of PRAK and ATF2. Next, the hypothesis that...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chun, Hockerman, Susan, Jacobsen, E. Jon, Alippe, Yael, Selness, Shaun R., Hope, Heidi R., Hirsch, Jeffrey L., Mnich, Stephen J., Saabye, Matthew J., Hood, William F., Bonar, Sheri L., Abu-Amer, Yousef, Haimovich, Ariela, Hoffman, Hal M., Monahan, Joseph B., Mbalaviele, Gabriel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2018
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940269/
https://www.ncbi.nlm.nih.gov/pubmed/29549113
http://dx.doi.org/10.1084/jem.20172063

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940269/
https://www.ncbi.nlm.nih.gov/pubmed/29549113
http://dx.doi.org/10.1084/jem.20172063

Ejemplares similares